Biotech Medics Ne Stock Performance
| BMCS Stock | USD 0.02 0 13.57% |
Biotech Medics holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 8.52, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biotech Medics will likely underperform. Use Biotech Medics treynor ratio, as well as the relationship between the semi variance and rate of daily change , to analyze future returns on Biotech Medics.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Biotech Medics Ne are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental indicators, Biotech Medics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Biotech |
Biotech Medics Relative Risk vs. Return Landscape
If you would invest 1.00 in Biotech Medics Ne on November 3, 2024 and sell it today you would earn a total of 0.59 from holding Biotech Medics Ne or generate 59.0% return on investment over 90 days. Biotech Medics Ne is currently generating 5.7124% in daily expected returns and assumes 38.5365% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Biotech, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biotech Medics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotech Medics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Biotech Medics Ne, and traders can use it to determine the average amount a Biotech Medics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1482
| Best Portfolio | Best Equity | BMCS | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 38.54 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Biotech Medics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotech Medics by adding it to a well-diversified portfolio.
Biotech Medics Fundamentals Growth
Biotech Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biotech Medics, and Biotech Medics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotech Pink Sheet performance.
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.24) % | |||
| Current Valuation | 9.68 M | |||
| Shares Outstanding | 172.36 M | |||
| Price To Earning | (0.47) X | |||
| Price To Sales | 3.30 X | |||
| Revenue | 469.8 K | |||
| EBITDA | 33.35 K | |||
| Cash And Equivalents | 1.31 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.02 X | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 5.08 M | |||
| Retained Earnings | (1.75 M) | |||
| Current Asset | 27 K | |||
| Current Liabilities | 2.01 M | |||
About Biotech Medics Performance
Assessing Biotech Medics' fundamental ratios provides investors with valuable insights into Biotech Medics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Biotech Medics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
BioTech Medics, Inc. operates as a medical-based holding company. The company was incorporated in 1997 and is based in Southlake, Texas with laser pain centers in Texas, California, New Mexico, and Florida. Biotech Medics is traded on OTC Exchange in the United States.Things to note about Biotech Medics Ne performance evaluation
Checking the ongoing alerts about Biotech Medics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biotech Medics Ne help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biotech Medics Ne is way too risky over 90 days horizon | |
| Biotech Medics Ne has some characteristics of a very speculative penny stock | |
| Biotech Medics Ne appears to be risky and price may revert if volatility continues | |
| The company has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biotech Medics until it has trouble settling it off, either with new capital or with free cash flow. So, Biotech Medics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biotech Medics Ne sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biotech to invest in growth at high rates of return. When we think about Biotech Medics' use of debt, we should always consider it together with cash and equity. | |
| Biotech Medics Ne reported the previous year's revenue of 469.8 K. Net Loss for the year was (603.72 K) with profit before overhead, payroll, taxes, and interest of 408.14 K. |
- Analyzing Biotech Medics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotech Medics' stock is overvalued or undervalued compared to its peers.
- Examining Biotech Medics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotech Medics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotech Medics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biotech Medics' pink sheet. These opinions can provide insight into Biotech Medics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biotech Pink Sheet Analysis
When running Biotech Medics' price analysis, check to measure Biotech Medics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Medics is operating at the current time. Most of Biotech Medics' value examination focuses on studying past and present price action to predict the probability of Biotech Medics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Medics' price. Additionally, you may evaluate how the addition of Biotech Medics to your portfolios can decrease your overall portfolio volatility.